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Abstract We have studied the biological properties of a new 
human CC chemokine, CKß8, consisting of 99 amino acids 
including six cysteines. CKß8 mRNA transcripts were induced in 
monocytes by IL-Iß and, to a lesser extent, by IFNy, and were 
detected in RNA extracted from normal human liver and 
gastrointestinal tract. CKß8 is chemotactic for monocytes, but 
is inactive on IL-2 conditioned T lymphocytes, eosinophils and 
neutrophils. Desensitization experiments indicate that CKß8 and 
MIP- lß completely share receptors on monocytes and that the 
CKß8 receptor, which appears to differ from the known ones, is 
also recognized by MCP-1, MCP-2, MCP-3, MCP-4, M l P - l a 
and RANTES. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Chemokines are small proteins that regulate leukocyte re-
cruitment in inflammation and immunity. They are character-
ized by four conserved cysteines linked to disulfide bonds and 
are subdivided into two groups, C X C and C C chemokines, 
depending on the arrangement of the first two cysteines which 
are separated by one amino acid or are adjacent [1-3]. C X C 
chemokines act mainly on neutrophils and activated T lym-
phocytes [3], while C C chemokines have a broader spectrum 
of activity and can attract monocytes [4,5], lymphocytes [6-8], 
basophils [9,10], and eosinophils [11,12]. We have studied the 
biological activities of a novel C C chemokine, CKß8 , that was 
identified within a large-scale sequencing program [13], and 
show here that CKß8 acts predominantly on monocytes. 
2. Materials and methods 
2.1. Cloning and expression 
The coding sequence of the novel chemokine was amplified by PCR 
from a human aortic endothelial cell cDNA library (Human Genome 
Sciences Inc., Rockville, MD). The cDNA was cloned into a baculo-
virus vector (BaculoGold®; Pharmingen, San Diego, CA), and the 
mature protein, CKß8, was expressed in Sf9 insect cells (ATCC CRL 
1711). The protein was purified from the supernatant of serum-free 
SF9 cell cultures in the presence of protease inhibitors (20 mg/ml 
Pefabloc SC; Boehringer, Mannheim, Germany, 1 mg/ml leupeptin, 
1 mg/ml E64, and 1 mM EDTA) by three chromatography steps: 
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cation exchange, heparin affinity, and size exclusion (poros 50 HS, 
poros 20 HE1, Perseptive Biosystem, and Sephacryl S200 HR; Phar-
macia Fine Chemicals, Piscataway, NJ) [13]. 
2.2. Chemokines 
MCP-1, MCP-2, MCP-3, RANTES, MlP-la and MIP-lß were 
chemically synthesized by Dr. Ian Clark-Lewis (Biomédical Research 
Centre and Department of Biochemistry, University of British Colum-
bia, Vancouver, Canada) according to established protocols [14]. 
MCP-4 was cloned and expressed as described [15]. 
2.3. Human cells and tissues 
Monocytes [5], lymphocytes [16], and neutrophils [17] were isolated 
from donor-blood buffy coats. Lymphocytes were cultured in presence 
of IL-2 as previously described [16]. Fresh blood of healthy individ-
uals was used to purify eosinophils by dextran sedimentation followed 
by Percoll density-gradient and negative selection with anti-CD 16 
monoclonal antibody (mAb)-coated magnetic beads [11]. For RNA 
extraction monocytes were used immediately after purification or fol-
lowing culture for 2, 8, 24, 48 h in the presence or absence of 10 ng/ml 
IL-lß or 100 U/ml IFNy. Normal human tissues were collected for 
RNA extraction with permission of the Local Ethical Committee from 
brain-dead organ donors. 
2.4. Northern blot analysis 
Total RNA from human tissues and leukocytes was extracted by 
the acid guanidinium thiocyanate phenol-chloroform method [18] or 
the RNAzol B method as recommended by the supplier (Tel-Test Inc., 
Friendswood, TX). Samples of 10 (ig RNA were fractionated on 1.2% 
denaturing agarose-formaldehyde gels, vacuum-transferred onto Ny-
tran membranes and immobilized. RNA from LPS-stimulated mono-
cytes was used to generate the probe for CKß8 with the follow-
ing primers: antisense 5'-TAA TCT AGA CTT CCT GGT CTT 
GAT CCG and sense 5'-TAT CTG CAG CCT CAT GCT TGT 
TAC TGT. The amplified PCR product was subcloned into pT7T3 
18U plasmid (Pharmacia) and sequenced. This 346-bp PCR fragment, 
as well as the 206-bp fragment for IL-8 corresponding to the position 
179 to 385 of the published cDNA 3-10C [19] and the 345-bp frag-
ment for RANTES corresponding to the position 27 to 372 of the 
published cDNA [20] were labeled with [a-32P]dATP using a random 
primer labeling kit (Boehringer Ltd., Mannheim, Germany). Hybrid-
ization was performed with 2 X106 cpm/ml of the labelled probe in the 
presence of 50% formamide at 42°C for 18 h [21]. Membranes were 
washed to a stringency of 0.2XSSC, 0.1% SDS at 65°C and exposed 
to screens which were subsequently analyzed using a phosphorimager 
(Molecular Dynamics Inc., Sunnyvale, CA) and the ImageQuant soft-
ware. After each hybridizatoin, the probe was removed by washing in 
50% formamide, 0.1 XSSC, 0.1% SDS at 65°C for 30 min. 
2.5. In vitro chemotaxis 
Chemotaxis was assessed in 48-well chambers (Neuro Probe, Cabin 
John, MD) using polyvinylpyrrolidone-free polycarbonate membranes 
(Nucleopore, Neuro Probe, Cabin John, MD) with 5-uin pores for 
monocytes, neutrophils and eosinophils, and 3-um pores for lympho-
cytes as previously described [5,16,22]. All assays were done in tripli-
cate, and the migrated cells were counted in five randomly selected 
fields at 1000-fold magnification. Spontaneous migration was deter-
mined in the absence of chemoattractant. 
2.6. Enzyme release 
The release of /V-acetyl-ß-D-glucosaminidase was tested in mono-
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CKß8 RVTKDAETEFMMSKLPLENPVLLDRFHATSADCCISYTPRSIPCSLLESYFETN.SEC 
MlP-la ASLAAD-PTACCF S-Q--QNFIAD S.-QC 
MIP-lß APMGSDPPTACCF A-KL-RNFVVD-Y-- S.-LC 
MCP-3 QPVGIN--TTCCYRFINKK--KQR RR-TS-HC 
1-309 SKSMQVPFSRCCF-FAEQE--LRAILC-RN-S.-IC 
CKß8 SKPGVIFLTKKGRRFCANPSDKQVQVCMRMLKLDTRIKTRKN 
MIP-la RS-QVC-D--EEW--KYVSD-E-SA 
MIP-lß -Q-A-V-Q--RSKQVC-D--ESW--EYVYD-E-N 
MCP-3 PREA K--LDKEIC-D-TQ-W--DF-KH-DKK-QTPKL 
1 - 3 0 9 -NE-L- -KL-R-KEAC-LDTVGW—RHRK--RHCPSKRK 
Fig. 1. Amino acid sequence of CKß8 aligned with MIP-la, MIP-lß, MCP-3 and 1-309. Identical amino acids are represented by hyphens. 
cytes. In brief, samples of 1.2 X 106 monocytes in 0.3 ml of prewarmed 
medium (136 mM NaCl, 4.8 mM KC1, 1.2 mM KH 2P0 4 , 1 mM 
CaCl2, 20 mM Hepes, pH 7.4, 5 mM D-glucose, and 1 mg/ml fatty 
acid-free BSA) were pretreated for 2 min with cytochalasin B (2.7 mg/ 
ml) and then stimulated with a chemokine. The reaction was stopped 
after 3 min by cooling on ice and centrifugation, and the enzyme 
activity was determined in the supernatant [5]. The release of elastase 
was tested in neutrophils as described previously [17]. 
2.7. Cytosolic free Ca2+ concentration ([Ca1+]\) changes 
Monocytes, eosinophils, neutrophils and lymphocytes loaded with 
Fura-2 (0.2 nmol/106 cells) were stimulated with a chemokine, and 
[Ca2+]i-related fluorescence changes were recorded [23]. The same 
asssay was used to test receptor desensitization in monocytes after 
repeated chemokine stimulation at 90-s intervals [5]. 
2.8. Treatment with B. pertussis toxin (PTx) 
Monocytes (107 cells/ml in 130 nM NaCl, 4.6 mM KC1, 5.0 mM 
NaHCOs, 0.05 mM CaCl2, 20 mM Hepes (pH 7.4), and 5 mM 
D-glucose) were incubated for 90 min in the presence or absence 
of 2 mg/ml PTx. Cells were then washed, resuspended in 136 mM 
NaCl, 4.8 mM KC1, 1 mM CaCl2, 5 mM glucose, 20 mM Hepes 
(pH 7.4), and immediately used for analysis of [Ca2+]i changes 
[24]. 
Fig. 2. CKß8, IL-8 and RANTES expression on monocytes. Total RNA from human monocytes was analyzed at different time points. Cells 
were cultured in the presence or absence of IL-Iß or IFNy. A representative experiment out of five is shown. 
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Fig. 3. A: Release of JV-acetyl-ß-D-glucosaminidase from cytochalasin B-treated human blood monocytes in response to CKß8 and other CC 
chemokines. Enzyme activity is presented in arbitrary fluorescence units. One out of three similar experiments performed with cells from differ-
ent donors is shown. B-D: Chemotactic responses of human monocytes (B), IL-2 conditioned T lymphocytes (C) and eosinophils (D). Numbers 
of migrating cells per five high-power fields are given. Mean ± SEM of five experiments performed with cells from different donors. 
3. Results 
3.1. CK$8 sequence 
The purified chemokine (see Section 2) yielded a single band 
with an apparent molecular mass of 11 kDa and no evidence 
for contaminant proteins on SDS-PAGE. Laser desorption 
mass spectrometry resolved a single peak with a molecular 
mass of 11 284 ± 30. The protein consists of 99 amino acids 
and has an unusually long NH2-terminal domain of 32 amino 
acids preceding the first cysteine. Amino acid identities be-
tween CKß8 and the reference chemokines are 50% for 
MlP-la, 41% for MIP-lß, 37% for MCP-3, 33% for MCP-
1, 32% for 1-309, and 31% for RANTES. CKß8 contains two 
cysteines in addition to the four conserved ones (Fig. 1). 
3.2. Expression 
As shown in Fig. 2, CKß8 mRNA expression was transi-
ently induced in monocytes by adherence with a maximum at 
8 h. Stimulation with either IL-Iß or IFNy increased CKß8 
mRNA levels with a similar time course. The effect of IL-Iß, 
however, was considerably more pronounced than that of 
IFNy. The expression of IL-8 and RANTES was also as-
sessed. Transcripts for IL-8 were induced with a similar time 
course by IL-Iß, but not by IFNy which was inhibitory. By 
contrast, RANTES was constitutively expressed and no 
changes were observed upon stimulation. Expression of 
CKß8 was also tested by Northern analysis of RNA extracted 
from lung, pleura, thymus, esophagus, stomach, duodenum, 
jejunum, ileum, colon, pancreas, liver, spleen, kidney and uri-
nary bladder. Positive signals were obtained for liver, jeju-
num, ileum, and colon (data not shown). 
3.3. Enzyme release in monocytes 
The activity of CKß8 was tested on monocytes, by measur-
ing the release of the lysosomal enzyme iV-acetyl-ß-D-glucosa-
minidase, a test that is particularly suited for quantitative 
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Fig. 4. Cross-desensitization of human blood monocytes. Fura-2-loaded monocytes were stimulated sequentially at 90-s intervals with 100 nM 
CKß8 and other CC chemokines, and [Ca2+];-dependent fluorescence changes were recorded. The tracings are representative for three separate 
experiments that were performed under identical conditions with cells from different donors. 
purposes [5]. As shown in Fig. 3A, the effect of CKß8 was 
concentration dependent with a threshold at 10 nM and a 
steady increase up to 1000 nM. The activity was comparable 
to that of MIP-lß, but was clearly lower than that of MIP-lcc 
and RANTES, and MCP-1 which is a very potent stimulus of 
exocytosis. Like MIP-lß and all the other CC chemokines, 
CKß8 did not induce elastase release in neutrophils (data 
from three independent experiments, not shown). 
lymphocytes and eosinophils (Fig. 3B-D). A significant migra-
tion response was obtained only with monocytes where the 
activity of CKß8 was identical in terms of efficacy and po-
tency to that of MIP-lß. In agreement with former studies [5], 
MCP-1 was more potent. CKß8 was completely inactive on 
IL-2 conditioned lymphocytes, which responded to MCP-1 
and MIP-lß, eosinophils which showed the expected response 
to eotaxin, and neutrophils (data not shown). 
3.4. In vitro chemotaxis 3.5. Calcium mobilization 
The chemotactic activity of CKß8 was tested in monocytes, A rapid and transient rise in [Ca2+]i was observed after 
U. Forssmann et al.lFEBS Letters 408 (1997) 211-216 215 
CKß8 stimulation of monocytes. The rate and the magnitude 
of the rise increased with the concentration. The threshold of 
calcium mobilization was approximately 30 nM and maxi-
mum values were obtained at chemokine concentrations of 
100 nM. In agreement with the lack of functional activities 
CKß8 did not induce [Ca2+]; changes in lymphocytes, eosino-
phils, or neutrophils up to a concentration of 100 nM. 
3.6. Receptor desensitization 
Receptor usage by CKß8 and other CC chemokines was 
assessed in monocytes by monitoring [Ca2+]j changes after 
sequential stimulation. As shown in Fig. 4, treatment of 
monocytes with MCP-1, MCP-2 (not shown), MCP-3, 
MCP-4, RANTES, MIP-loc and MIP-lß abolished respon-
siveness to CKß8. Prestimulation with CKß8 did not affect 
the response of the MCPs, and only slightly reduced the re-
sponse of RANTES and MlP-la. In contrast CKß8 com-
pletely desensitized the cells toward MIP-lß. These results 
indicate that CKß8 and MIP-lß completely share receptors 
on monocytes, and that all the other chemokines tested rec-
ognize the receptor that mediates the activity of CKß8 on 
monocytes. 
We have cultured monocytes for 24 h under standard con-
ditions in RPMI supplement with 10% FCS, and have found 
that desensitization of the response of MIP-lß by CKß8 was 
largely lost (data not shown). This experiment suggests the 
up-regulation of a receptor that recognizes MIP-lß but not 
CKß8, possibly CCR5. 
3.7. Effect of B. pertussis toxin 
Pretreatment of monocytes with 2 |Xg/ml PTx for 90 min at 
37°C completely abrogated [Ca2+]; changes induced by 100 
nM CKß8 or MIP-lß, suggesting that the receptor shared 
by these chemokines is coupled to PTx-sensitive G proteins. 
The PTx pretreatment also virtually abrogated the [Ca2+]i 
changes elicited by MCP-1 which was used as control (data 
not shown) in agreement with former observations [25]. 
4. Discussion 
We have described a CC chemokine, CKß8, that is struc-
turally and functionally related to MlP-la and MIP-lß and 
acts on human monocytes, but not on eosinophils, neutrophils 
and IL-2 conditioned T lymphocytes. The same chemokine 
was recently shown to inhibit colony formation by myeloid 
progenitor cells, and was named myeloid progenitor inhibi-
tory factor 1 (MPIF-1) [13]. 
CKß8 has an unusually long NH2-terminal domain of 32 
amino acids preceding the first two conserved cysteines. Like 
the CC chemokine 1-309, CKß8 has two cysteines in addition 
to the four conserved ones, but they are located at different 
positions. 1-309 was also reported to act specifically on mono-
cytes [26]. Three CC chemokines with long NH2-terminal do-
main and six cysteines at corresponding positions, C10/MRP-
1 [27], MIP-lx [28] and CCF-18/MRP-2 [29,30], were previ-
ously described in mice. They show a moderate degree of 
sequence identity with CKß8 (33-37%). These murine chemo-
kines were shown to inhibit colony formation by myeloid 
progenitors cells, an activity that they share with human 
MlP-la and CKß8. 
The expression of CKß8, as assessed by Northern blotting 
in PBL differs, at least in part, from that of IL-8 and 
RANTES. CKß8 mRNA was induced upon adherence to 
plastic and was enhanced by IFNy and much more efficiently 
by IL-Iß. Expression of IL-8 was also enhanced by IL-Iß in 
agreement with previous reports [31,32], but not by IFNy as 
previously shown in monocytes [33,34] and granulocytes [35]. 
Under similar conditions RANTES was expressed constitu-
tively and the level of transcripts was not affected by IL-Iß 
nor IFNy [36]. 
The similarity of the response of monocytes to CKß8 and 
MIP-lß and the results of the desensitization experiments 
suggest that CKß8 acts via a novel receptor. Since the 
[Ca2+]i changes induced by CKß8 were abrogated by pretreat-
ment with MCP-1, MCP-3, MCP-4, RANTES, MIP-loc and 
MIP-lß. the CKß8 receptor appears to recognize most of the 
CC chemokines. A complete cross-desensitization was ob-
served on monocytes, only between CKß8 and MIP-lß. This 
observation could be taken to suggest that CCR5, the only 
receptor positively known to bind MIP-lß, might also bind 
CKß8. This hypothesis, however, must be rejected because 
CKß8 was inactive on IL-2 conditioned T lymphocytes [16], 
and did not prevent the [Ca2+]; changes induced by MIP-lß in 
monocytes cultured for 24 h to up-regulate CCR5 [37]. Since 
CKß8 did not induce [Ca2+]i changes or chemotaxis in lym-
phocytes and eosinophils, there is strong evidence that it does 
not act via CCR1, CCR2, CCR3 or CCR5. Further evidence 
for this conclusion stems from the data on monocytes, where 
CKß8 pretreatment had little effect on the subsequent stimu-
lation with MCPs, RANTES or MlP-la. CCR4 can be also 
excluded as receptor for CKß8 based on the report of Power 
et al. [38], showing that MIP-lß does not induce [Ca2+]; mo-
bilization on CCR4 transfectants. 
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